Cytokinetics (CYTK) News Today

Healthcare of Ontario Pension Plan Trust Fund bought a new stake in Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 30,000 shares of the biopharmaceutical company's stock,

American International Group Inc. lifted its stake in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 245.9% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 176,072 shares of the biopharmaceutic

Ameritas Investment Partners Inc. grew its position in Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 230.5% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 31,003 shares of the biopharmaceutical company's stock af

Westfield Capital Management Co. LP bought a new position in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) in the first quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 731,386 shares of the biopharmaceutical company's s

Cytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) was the recipient of a significant growth in short interest in the month of June. As of June 30th, there was short interest totalling 17,380,000 shares, a growth of 8.4% from the June 15th total of 16,040,000 shares. Based on an average daily trading volume, of 1,970,000 shares, the short-interest ratio is currently 8.8 days. Currently, 15.7% of the company's stock are short sold.

Entropy Technologies LP increased its stake in Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 110.6% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 19,433 shares of the biopharmaceutical company's stock after ac

Cytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) Director B Lynne Parshall sold 5,000 shares of the stock in a transaction dated Monday, July 15th. The shares were sold at an average price of $55.82, for a total transaction of $279,100.00. Following the completion of the sale, the director now owns 20,600 shares of the company's stock, valued at approximately $1,149,892. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Susquehanna Fundamental Investments LLC bought a new position in Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 67,076 shares of the biopharmaceutica

Lisanti Capital Growth LLC cut its holdings in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 64.7% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 17,805 shares of the biopharmaceutica

Mutual of America Capital Management LLC increased its position in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 240.5% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 58,437 sh

Cytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the eighteen research firms that are covering the stock, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation and fifteen

Cytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) CEO Robert I. Blum sold 11,500 shares of the stock in a transaction on Wednesday, July 10th. The shares were sold at an average price of $54.29, for a total value of $624,335.00. Following the sale, the chief executive officer now owns 399,412 shares in the company, valued at $21,684,077.48. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

BNP Paribas Financial Markets trimmed its holdings in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 13.7% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 171,551 shares of the biopharmaceutical company

FORA Capital LLC boosted its holdings in Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 758.0% during the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 82,776 shares of the biopharmaceutical company's stock after acquiring

Van ECK Associates Corp acquired a new position in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 57,893 shares of the bio

Retirement Systems of Alabama bought a new position in Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 123,132 shares of the biopharmaceutical company's sto

Cytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) CEO Robert I. Blum sold 11,500 shares of the company's stock in a transaction on Monday, July 1st. The stock was sold at an average price of $54.05, for a total value of $621,575.00. Following the completion of the sale, the chief executive officer now owns 405,145 shares of the company's stock, valued at $21,898,087.25. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

JPMorgan Chase & Co. cut their price objective on Cytokinetics from $77.00 to $65.00 and set an "overweight" rating on the stock in a report on Monday.

Los Angeles Capital Management LLC bought a new position in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor bought 17,817 shares of

Vanguard Group Inc. raised its stake in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 2.5% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 11,016,889 shares of the biopharmaceutical company's stock after purchasing an add

Cytokinetics (NASDAQ:CYTK) Shares Gap Down After Insider Selling

Fisher Asset Management LLC purchased a new position in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 536,046 shares of the biopharmace

Cytokinetics (NASDAQ:CYTK) Stock Price Down 3.2%

HC Wainwright reissued a "buy" rating and issued a $90.00 target price on shares of Cytokinetics in a report on Monday.

Virtu Financial LLC purchased a new position in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 46,768 shares of the biopharmaceutical company's stock,

Cytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) was the recipient of a significant growth in short interest in the month of May. As of May 31st, there was short interest totalling 16,420,000 shares, a growth of 15.7% from the May 15th total of 14,190,000 shares. Currently, 14.9% of the shares of the company are short sold. Based on an average daily trading volume, of 2,290,000 shares, the short-interest ratio is presently 7.2 days.

Shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) have earned an average recommendation of "Moderate Buy" from the seventeen research firms that are covering the company, MarketBeat reports. Three investment analysts have rated the stock with a hold recommendation and fourteen ha

Osterweis Capital Management Inc. bought a new stake in Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 17,340 shares of the biopharmaceut

Great Point Partners LLC lowered its stake in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 16.7% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 500,000 shares of th

Cytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) EVP Fady Ibraham Malik sold 7,788 shares of the firm's stock in a transaction that occurred on Tuesday, June 11th. The stock was sold at an average price of $53.04, for a total transaction of $413,075.52. Following the completion of the sale, the executive vice president now owns 135,004 shares in the company, valued at approximately $7,160,612.16. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Bellevue Group AG trimmed its holdings in Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 49.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 18,900 shares of the biopharmaceutical company's s

Superstring Capital Management LP purchased a new stake in Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 177,603 shares of the bi